REG-Hofseth BioCare ASA: THIRD QUARTER 2026 FINANCIAL REPORT
Globe Newswire•06/11/2026•02:15 ET
2
Key Highlights
- ➤Q3 revenue NOK 83.5 million, highest quarterly level, up from NOK 54.9 million
- ➤EBITDA turned positive at NOK 4.4 million, improving NOK 25.6 million year-on-year
- ➤Pet nutrition revenue NOK 35.2 million, up 39.5% year-on-year on higher pricing
- ➤Human nutrition revenue rose 54% year-on-year to NOK 32.2 million
- ➤June private placement raised NOK 144.5 million, including NOK 73.2 million receivables conversion
Expert Statements
Jon Olav Ødegård, CEO of Hofseth BioCare ASA
“Hofseth BioCare is a Norwegian consumer and pet health company founded on the core values of sustainability, optimal utilization of natural resources and full traceability.”
HBC recorded total operating revenues of NOK 83.5 million in the third quarter of 2026, compared to NOK 54.9 million in the same period last year, which is the highest quarterly revenue HBC has recorded. Net operating revenues were NOK 82.1 million, up from NOK 54.8 million in Q3 2025.
EBITDA for the quarter was positive NOK 4.4 million, compared to negative NOK 21.1 million in Q3 2025. The Operational EBITDA* amounted to NOK 10.3 million (negative NOK 12.9 million in Q3 2025), excluding non-recurring and strategic development costs such as clinical trials and R&D expenses, and Berkåk project costs.
Get started
Create a free account to read the full story.